Latest Technology News

Metals Australia has launched a 12-hole drilling campaign to delineate and extend its promising Vanadium-Titanium-Magnetite discovery in Western Australia, aiming to unlock further value from this critical minerals project.

Battery Age Minerals has initiated a targeted reconnaissance and sampling program at the Apex Germanium-Gallium Project in Utah, marking the first modern exploration in decades at this historically significant site. The move expands their strategic critical metals footprint across the US and Europe.

Lodestar Minerals has appointed two former heavy rare earths experts from MP Materials and Lynas Rare Earths to spearhead its U.S. downstream magnet and supply chain strategy, following its planned acquisition of the Virgin Mountain project in Arizona.

First Graphene has completed its initial industrial-scale shipment of graphene-enhanced TPU masterbatch to PT Alasmas, marking a key milestone in commercialising advanced materials for durable work boots in Southeast Asia.

Altech Batteries reveals Sodium-Nickel-Chloride (SNC) batteries achieve an exceptionally low failure rate of 0.6-1.5% over 15+ years in harsh South African conditions, significantly outperforming lithium-ion and lead-acid alternatives.

National Australia Bank reported a modest rise in underlying profit for FY25, driven by robust revenue and volume growth in the second half, alongside continued technology modernization and sustainability progress.

National Australia Bank reported a 1% increase in underlying profit for FY25, with strong deposit growth and higher credit impairment charges marking the year. The bank maintained solid capital ratios and announced an 85 cent fully franked dividend.

National Australia Bank reported a 1% increase in underlying profit for FY25 with stable cash earnings and a steady fully franked dividend of 85 cents per share. The bank’s refreshed strategy shows early momentum despite rising credit impairment charges.

National Australia Bank reported a 1.2% revenue increase to $20.872 billion in FY25, while net profit dipped 2.9% to $6.759 billion. The bank highlighted progress in customer-centric strategy, technology modernization, and sustainability initiatives.

Immuron Limited has secured FDA approval for its IMM-529 Investigational New Drug application, clearing the way for a Phase 2 clinical trial targeting Clostridioides difficile infection. This milestone marks a significant step forward for a novel oral antibody therapy addressing a critical infectious disease with high recurrence rates.

Verbrec Limited is streamlining its business by selling its Competency Training division for $11.5 million and acquiring Alliance Automation for $5.5 million, significantly boosting its digital and automation capabilities.

Nova Eye Medical reported a 20% year-on-year revenue increase in Q1 FY26, reaffirming its FY26 sales guidance and targeting breakeven EBITDA by June 2026 amid cautious commercial expansion.